Eris Lifesciences Limited — PPTs, 20-05-2026: Investor Presentation

Eris Lifesciences delivered a solid FY26, with consolidated revenue up 8.1% to Rs. 3,129 Cr and EBIDTA increasing 10.1% to Rs. 1,120 Cr, achieving a 36% margin. Domestic Branded Formulations (DBF) grew 11% to Rs. 2,778 Cr, driven by strong performance in Insulin (+32% vs market) and Derma (+14.2% vs market) segments. However, DBF saw ~Rs. 100 Cr in lost revenue due to delayed launches and manufacturing issues. International business revenue grew 7% to Rs. 348 Cr, though Q4 faced supply chain disruptions.

A key growth driver is the strong debut of its Gx Semaglutide brand 'Sundae', which already ranks #1 in injectables by volume and #2 by value in April. Eris plans to in-source Sundae Pen manufacturing from Q2 FY27 for improved margins. Recent EU-GMP inspection observations are delaying new EU-CDMO product commercialization, but existing business remains largely unaffected.

FY26 reported PAT jumped 73% to Rs. 648 Cr (boosted by a deferred tax adjustment), with operational EPS at Rs. 36. Net debt reduced to Rs. 2,255 Cr (2x EBIDTA). For FY27, the company forecasts DBF revenue growth at 1.3x its market growth and international business growth of 18-20%, with similar EBIDTA margins across segments. Resolving EU audit points is a priority for future CDMO commercialization.